Application effects of Sacubitril/Valsartan combined with Ticagrelor and Aspirin in patients with acute myocardial infarction undergoing percutaneous coronary intervention
Objective:To observe application effects of Sacubitril/Valsartan combined with Ticagrelor and Aspirin in patients with acute myocardial infarction(AMI)undergoing percutaneous coronary intervention(PCI).Methods:The clinical data of 108 patients with AMI who underwent PCI in this hospital from September 2021 to September 2022 were retrospectively analyzed.According to different treatment methods,they were divided into control group and observation group,54 cases in each group.The control group was treated with Ticagrelor combined with Aspirin,while the observation group was treated with Sacubitril/Valsartan on the basis of those of the control group.The levels of ventricular remodeling indexes[left ventricular ejection fraction(LVEF),left ventricular mass index(LVMI),left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD)],myocardial enzyme indexes[creatine kinase(CK),lactate dehydrogenase(LDH),creatine kinase isoenzyme(CK-MB)]and inflammatory factors[interleukin-6(IL-6),high-sensitivity C-reactive protein(hs-CRP),tumor necrosis factor-α(TNF-α)],amino-terminal pro-brain natriuretic peptide(NT-proBNP),the exercise endurance[6-minute walking test(6MWT)],the incidence of adverse reactions,and the incidence of major adverse cardiovascular events(MACE)were compared between the two groups before and after the treatment.Results:After the treatment,the level of LVEF in the observation group was higher than that in the control group,the levels of LVMI,LVEDD and LVESD were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of CK,LDH,CK-MB,IL-6,hs-CRP and TNF-α in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the level of NT-proBNP in the observation group was lower than that in the control group,the 6MWT distance was longer than that in the control group,and the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).After 6 months of follow-up,the incidence of MACE in the observation group was 5.56%(3/54),which was lower than 18.52%(10/54)in the control group,and the difference was statistically significant(P<0.05).Conclusions:Sacubitril/Valsartan combined with Ticagrelor and Aspirin in the patients with AMI undergoing PCI can improve the levels of exercise endurance,improve the levels of ventricular remodeling indexes,and reduce the levels of myocardial enzyme indexes,inflammatory factors and NT-proBNP and the incidence of MACE.Moreover,it is superior to Ticagrelor combined with Aspirin treatment.
NETL
NSTL
万方数据
